Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 17-18/2012

01.09.2012 | review

Update on denosumab in postmenopausal osteoporosis—recent clinical data

verfasst von: Christian Muschitz, MD, Astrid Fahrleitner-Pammer, MD, Johannes Huber, MD, PhD, Elisabeth Preisinger, MD, Stefan Kudlacek, MD, Heinrich Resch, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 17-18/2012

Einloggen, um Zugang zu erhalten

Summary

Denosumab, a fully human monoclonal antibody against the key osteoclastogenic factor RANK ligand, is currently approved for the treatment of postmenopausal osteoporosis. Denosumab differs from bisphosphonates in many aspects, for example, its ability to act in the extracellular compartment and its likelihood to be distributed throughout the skeleton. In contrast, bisphosphonates have to be internalized by osteoclasts and are mainly located across bone surfaces. This could explain why patients with osteoporosis, who are already treated with bisphosphonates, might experience further benefit when switching to denosumab. Head-to-head studies revealed that transition to denosumab resulted in a greater increase of bone mineral density (BMD) and a greater reduction of bone turnover than did continued alendronate. Additional analyses of the phase 3 FREEDOM trial demonstrated that fracture reduction was particularly high in cortical bone, such as the wrist. In addition, denosumab treatment for a 5- and 8-year period showed sustained reduction in fracture risk, increase in BMD and continued to be well tolerated. The 7-year extension study of FREEDOM and a phase 3 trial evaluating denosumab for the treatment of male osteoporosis are still ongoing and will provide supportive data in the near future.
Literatur
2.
Zurück zum Zitat Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375:1729–36.PubMedCrossRef Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375:1729–36.PubMedCrossRef
3.
Zurück zum Zitat Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33.PubMedCrossRef Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–33.PubMedCrossRef
4.
Zurück zum Zitat Dempster DW. Primer on the metabolic bone diseases and disorders of bone metabolism. 7th ed. ASBMR: Washington; 2008. pp. 7–11. Dempster DW. Primer on the metabolic bone diseases and disorders of bone metabolism. 7th ed. ASBMR: Washington; 2008. pp. 7–11.
5.
Zurück zum Zitat Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.PubMedCrossRef Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.PubMedCrossRef
6.
Zurück zum Zitat Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1–S7.PubMedCrossRef Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1–S7.PubMedCrossRef
7.
Zurück zum Zitat Tsourdi E, Rachner TD, Rauner M, et al. Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol. 2011;165:833–40.PubMedCrossRef Tsourdi E, Rachner TD, Rauner M, et al. Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol. 2011;165:833–40.PubMedCrossRef
8.
Zurück zum Zitat Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28:63–82.PubMedCrossRef Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28:63–82.PubMedCrossRef
9.
Zurück zum Zitat Denosumab (Prolia®) Summary of product characteristics. Amgen Inc. Denosumab (Prolia®) Summary of product characteristics. Amgen Inc.
10.
Zurück zum Zitat Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–92.PubMedCrossRef Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–92.PubMedCrossRef
11.
Zurück zum Zitat Russell RGG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci. 2007;1117:209–57.PubMedCrossRef Russell RGG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci. 2007;1117:209–57.PubMedCrossRef
12.
Zurück zum Zitat Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53–62.PubMedCrossRef Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009;360:53–62.PubMedCrossRef
13.
Zurück zum Zitat Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022–33.PubMedCrossRef Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022–33.PubMedCrossRef
14.
Zurück zum Zitat Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81.PubMedCrossRef Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25:72–81.PubMedCrossRef
15.
Zurück zum Zitat Seeman E, Libanati C, Austin M, et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy. J Bone Mineral Res. 2011;26(Suppl 1):S22, #1064. Seeman E, Libanati C, Austin M, et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy. J Bone Mineral Res. 2011;26(Suppl 1):S22, #1064.
16.
Zurück zum Zitat Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.PubMedCrossRef Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.PubMedCrossRef
17.
Zurück zum Zitat Rizzoli R, Boonen S, Bone HG, et al. The effect of denosumab on vertebral fracture risk by type and subgroup: results from the FREEDOM trial. Osteoporosis Int. 2010;21(Suppl 1):357–8 (Abstract P841). Rizzoli R, Boonen S, Bone HG, et al. The effect of denosumab on vertebral fracture risk by type and subgroup: results from the FREEDOM trial. Osteoporosis Int. 2010;21(Suppl 1):357–8 (Abstract P841).
18.
Zurück zum Zitat Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96:1727–36.PubMedCrossRef Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96:1727–36.PubMedCrossRef
19.
Zurück zum Zitat Simon J, Recknor C, Moffet A, et al. Effects of Denosumab on radius BMD, strength, and wrist fractures: results from theFractureReductionEvaluation ofDenosumab inOsteoporosis Every 6Months (FREEDOM) Study. J Bone Mineral Res. 2011;26(Suppl 1):S20–21, #1062. Simon J, Recknor C, Moffet A, et al. Effects of Denosumab on radius BMD, strength, and wrist fractures: results from theFractureReductionEvaluation ofDenosumab inOsteoporosis Every 6Months (FREEDOM) Study. J Bone Mineral Res. 2011;26(Suppl 1):S20–21, #1062.
20.
Zurück zum Zitat Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–701.PubMedCrossRef Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694–701.PubMedCrossRef
21.
Zurück zum Zitat Bone HG, Chapurlat R, Libanati C, et al. Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. J Bone Mineral Res. 2011;26(Suppl 1):S22–23, #1065. Bone HG, Chapurlat R, Libanati C, et al. Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. J Bone Mineral Res. 2011;26(Suppl 1):S22–23, #1065.
22.
Zurück zum Zitat Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–9.PubMedCrossRef Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–9.PubMedCrossRef
23.
Zurück zum Zitat McClung MR, Lewiecki EM, Bolognese MA, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. J Bone Min Res. 2011;26:Abstract 1061. McClung MR, Lewiecki EM, Bolognese MA, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. J Bone Min Res. 2011;26:Abstract 1061.
24.
Zurück zum Zitat Orwoll E, Stubbe Teglbjærg C, Langdahl B, et al. A phase 3 Study of the efficacy and safety of denosumab in men with low bone mineral density: design of the ADAMO trial. J Bone Mineral Res. 2011;26(Suppl 1):#MO0442. Orwoll E, Stubbe Teglbjærg C, Langdahl B, et al. A phase 3 Study of the efficacy and safety of denosumab in men with low bone mineral density: design of the ADAMO trial. J Bone Mineral Res. 2011;26(Suppl 1):#MO0442.
Metadaten
Titel
Update on denosumab in postmenopausal osteoporosis—recent clinical data
verfasst von
Christian Muschitz, MD
Astrid Fahrleitner-Pammer, MD
Johannes Huber, MD, PhD
Elisabeth Preisinger, MD
Stefan Kudlacek, MD
Heinrich Resch, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 17-18/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0116-x

Weitere Artikel der Ausgabe 17-18/2012

Wiener Medizinische Wochenschrift 17-18/2012 Zur Ausgabe